---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026636"
form_type: "8-K"
ticker: null
cik: "0001785345"
company_name: "Landos Biopharma, Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:29:14.730182+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Landos Biopharma gets Nasdaq approval to transfer to Capital Market; 180-day bid price compliance extension

## Summary
- Transfer from Nasdaq Global Market to Nasdaq Capital Market effective Dec 15, 2022.
- Additional 180-day compliance period granted until June 12, 2023 to meet $1.00 minimum bid price.
- Company may effect a reverse stock split to cure the bid price deficiency if necessary.
- Failure to regain compliance could result in delisting, subject to appeal to a Nasdaq hearings panel.

## SEC filing metadata
- accession: 0000950170-22-026636
- form_type: 8-K
- cik: 0001785345
- company_name: Landos Biopharma, Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785345/000095017022026636/0000950170-22-026636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785345/000095017022026636/labp-20221213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026636
- JSON: https://secwatch.observer/filing/0000950170-22-026636.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026636.txt

## Key facts
- Listing & Compliance Notices
  Landos Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: The Company intends to actively monitor the bid price of its common stock and will consider available options, including a reverse stock split, to regain compliance with the listing requirements. There can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rule 5450(a)(1) or will otherwise be in compliance with other Nasdaq listing criteria. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Landos Biopharma, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785345/000095017022026636/0000950170-22-026636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.